Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib vs cediranib + saracatanib in relapsed metastatic clear cell renal cancer
2009-018014-20Phase 2Completed
- Sponsor
- NHS National Services Scotland
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cediranib and saracatinib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by NHS National Services Scotland. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.
02
Drugs
cediranibsaracatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2009-018014-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018014-20.